Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany
Similar Posts
Webinar – Clinical Experience of Using Nimotuzumab in Nasopharyngeal Cancer
ByInnokeysSpeaker: Dr. dr. Andhika Rachman, Sp.Pd-KHOM from MRCCC Siloam Hospital Indonesia
May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
ByInnokeysKowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….
Patent Pending for “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in numerous countries
ByInnokeysApplication for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…
August 2013: Nimotuzumab in MOGA Australia
ByInnokeysMedical Oncology Group of Australia
ASCO 2013 : Nimotuzumab Abstracts
ByInnokeysProfessor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeysMISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…